References
Greenberg JD, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010;69:380–386.
Gutierrez-Ureña S, Molina JF, García CO, Cuéllar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996;39:272–276.
Ohosone Y, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol. 1997;24:2299–2303.
Mori S, et al. Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases. PLoS ONE. 2016;11:e0154744.
Mehdi SR, Bhatt MLB. Metastasis of Solid Tumors in Bone Marrow: A Study from Northern India. Indian J Hematol Blood Transfus. 2011;27:93–95.
Ellis SM, Hansell DM. Imaging of Non-tuberculous (Atypical) Mycobacterial Pulmonary Infection. Clin Radiol. 2002;57:661–669.
Prince DS, et al. Infection with Mycobacterium avium Complex in Patients without Predisposing Conditions. N Engl J Med. 1989;321:863–868.
Carmier D, et al. Serious bronchopulmonary involvement due to chronic lymphocytic leukaemia. Eur Respir Rev. 2013;22:416–419.
Rahul E, et al. Large granular lymphocytic leukemia: a brief review. Am J Blood Res. 2022;12:17–32.
Fuhrman C, et al. Spectrum of CD4 to CD8 T-Cell Ratios in Lymphocytic Alveolitis Associated with Methotrexate-induced Pneumonitis. Am J Respir Crit Care Med. 2011;164:1186–1191.
World Health Organization (WHO) Classification of Tumours Editorial Board. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (beta version ahead of print). vol. 11 (International Agency for Research on Cancer Press, 2022).
Nowakowski GS, et al. Percentage of Smudge Cells on Routine Blood Smear Predicts Survival in Chronic Lymphocytic Leukemia. J Clin Oncol. 2009;27:1844–1849.
Loughran TP, et al. Leukemia of Large Granular Lymphocytes: Association with Clonal Chromosomal Abnormalities and Autoimmune Neutropenia, Thrombocytopenia, and Hemolytic Anemia. Ann Intern Med. 1985;102:169–175.
Senthil R, Visakh RA, Pratap T, Mahadevan P, Gangadharan VP. Atypical Presentation of T-Cell Large Granular Lymphocytic Leukemia Mimicking Pleural Malignancy on 18F-FDG PET/CT. Clin Nucl Med. 2019;44:e296.
Patatanian E, Thompson DF. A Review of Methotrexate-Induced Accelerated Nodulosis. Pharmacother J Hum Pharmacol Drug Ther. 2002;22:1157–1162.
Chater N, Vitányi P. Simplicity: a unifying principle in cognitive science? Trends Cogn Sci. 2003;7:19–22.
Redelmeier DA, Tan SH, Booth GL. The Treatment of Unrelated Disorders in Patients with Chronic Medical Diseases. N Engl J Med. 1998;338:1516–1520.
Kelly J. The Diagnostic Approach in Complex Patients: Parsimony or Plenitude? Am J Med. 2021;134:11–12.
Sokol L, Loughran TP. Large granular lymphocyte leukemia. Oncologist. 2006;11:263–273.
Acknowledgements:
We give our sincere appreciation and gratitude to our patient for her consent to the publication of this manuscript. We would also like to thank Dr. Loughran for his expert guidance on LGL leukemia, a disease which he first described and has since performed landmark research to further characterize.
Author information
Authors and Affiliations
Contributions
• Jasraj S. Raghuwanshi, BS—inpatient medical student for the patient; responsible for preparing first draft of the manuscript, elaborating on clinical reasoning strategy used in this case, literature review, and accessing and compiling lab results/radiological images.
• Nathan Roberts, MD—inpatient hematologist-oncologist for the patient, responsible for acquiring and reviewing hematopathological slides and providing interpretation, provided substantial content review and copyediting.
• Thomas P. Loughran, Jr., MD—international expert and first to describe LGL leukemia (Loughran, Jr. et al., 1985), advised on clinical presentation, symptomatology, and prognosis of LGL leukemia and its subtypes.
• Firas El Chaer, MD—outpatient hematologist for the patient, provided key details on follow-up and resolution of symptomatology following discontinuation of methotrexate, copyediting.
• Mark Girton, MD—hematopathology and lab medicine expert; advised on spread of hematolymphoid malignancies, subtypes of LGL leukemia by flow cytometry phenotype and prognosis, 2016 WHO diagnostic and clinical criteria for LGL leukemia, atypical nature of the lymphocytosis in this patient’s presentation, and accurately reporting lab results (CBC, BMP, flow cytometry); provided substantial content review and copyediting.
• Glenn Moulder, MD—inpatient internist for the patient, responsible for majority of inpatient workup and clinical reasoning, highlighted unique presentation and diagnostic challenge with concurrent methotrexate pneumonitis and LGL leukemia not yet described in the literature, copyediting.
Corresponding author
Ethics declarations
Conflict of Interest:
The authors declare that they do not have a conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Raghuwanshi, J.S., Roberts, N., Loughran, Jr., T. et al. Plurality Over Parsimony: When Two Diagnoses Are More Likely Than One. J GEN INTERN MED 39, 1257–1263 (2024). https://doi.org/10.1007/s11606-023-08585-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11606-023-08585-7